IMNM
VENTE TOTALE: 11 048 titres (~301 058,00 $ US)
- Insiders
- Barchas Isaac
- Total bought
- —
- Total sold
- $301,058
- Last activity
- 2026-08-12
- Last synced
-
2026-08-21 23:36:53
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-08-14
IMNM presents a structurally fragile investment case: despite adequate liquidity (score 85), the near-zero fundamental trend score (15) reflects a pre-revenue, cash-burning operation with no credible near-term path to…
The first sentence of the analysis written for IMNM on 2026-08-14 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 57.4% | 100.0% | 100.0% | 0.0% | 0.0% | |
| Ebit Margin | -3060.0% | -1697.3% | -204.9% | 0.0% | 0.0% | |
| Ebitda Margin | -3017.4% | -1674.1% | -199.7% | 0.0% | 0.0% | |
| Operating Profit Margin | -3084.8% | -3382.4% | -781.4% | 0.0% | 0.0% | |
| Pretax Profit Margin | -3060.0% | -3240.4% | -761.9% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | -3060.0% | -3240.4% | -761.9% | 0.0% | 0.0% | |
| Net Profit Margin | -3060.0% | -3240.4% | -761.9% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | -3060.0% | -3240.4% | -761.9% | 0.0% | 0.0% | |
| Current Ratio | 14.687 | 4.076 | 6.629 | 3.089 | 5.822 | |
| Quick Ratio | 14.687 | 4.076 | 6.629 | 3.089 | 5.822 | |
| Solvency Ratio | -4.288 | -4.924 | -3.702 | -4.905 | -2.460 | |
| Cash Ratio | 14.525 | 2.640 | 4.521 | 2.772 | 5.061 | |
| Price To Earnings Ratio | -8.840 | -2.124 | -1.989 | -0.715 | -6.056 | |
| Price To Earnings Growth Ratio | 0.172 | 0.301 | -0.027 | -0.016 | -0.227 | |
| Forward Price To Earnings Growth Ratio | 0.172 | 0.301 | -0.027 | -0.016 | -0.227 | |
| Price To Earnings Diluted Ratio | -8.840 | -2.124 | -1.989 | -0.715 | -6.056 | |
| Price To Earnings Diluted Growth Ratio | 0.172 | 0.301 | -0.027 | -0.016 | -0.227 | |
| Price To Book Ratio | 2.958 | 3.437 | 1.771 | 1.609 | 3.103 | |
| Price To Sales Ratio | 270.321 | 68.881 | 15.147 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -9.353 | -3.790 | -25.280 | -0.926 | -8.169 | |
| Price To Operating Cash Flow Ratio | -9.828 | -5.621 | -28.056 | -0.934 | -8.205 | |
| Debt To Assets Ratio | 0.006 | 0.020 | 0.011 | 0.012 | 0.005 | |
| Debt To Equity Ratio | 0.006 | 0.027 | 0.014 | 0.017 | 0.007 | |
| Debt To Capital Ratio | 0.006 | 0.026 | 0.014 | 0.017 | 0.007 | |
| Long Term Debt To Capital Ratio | 0.006 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.077 | 1.326 | 1.239 | 1.444 | 1.202 | |
| Working Capital Turnover Ratio | 0.018 | 0.062 | 0.203 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -4.244 | -2.040 | -0.347 | -3.914 | -1.874 | |
| Operating Cash Flow Sales Ratio | -27.506 | -12.255 | -0.540 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.051 | 1.483 | 1.110 | 1.009 | 1.004 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | -7,252.000 | -2,394.600 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | -7,380.200 | -2,520.400 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -49.525 | -22.929 | -4.587 | -98.591 | -57.495 | |
| Capital Expenditure Coverage Ratio | -19.713 | -2.071 | -9.107 | -115.685 | -230.709 | |
| Dividend Paid And Capex Coverage Ratio | -19.713 | -2.071 | -9.107 | -115.685 | -230.709 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -5.857 | -3.199 | -4.118 | -0.187 | -4.202 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 57.4% | ▼-42.6% | ▲5.9% |
| Ebit Margin | -3060.0% | ▼-1362.7% | ▼-2067.5% |
| Ebitda Margin | -3017.4% | ▼-1343.3% | ▼-2039.2% |
| Operating Profit Margin | -3084.8% | ▲297.6% | ▼-1635.1% |
| Pretax Profit Margin | -3060.0% | ▲180.4% | ▼-1647.5% |
| Continuous Operations Profit Margin | -3060.0% | ▲180.4% | ▼-1647.5% |
| Net Profit Margin | -3060.0% | ▲180.4% | ▼-1647.5% |
| Bottom Line Profit Margin | -3060.0% | ▲180.4% | ▼-1647.5% |
| Current Ratio | 14.687 | ▲10.611 | ▲7.827 |
| Quick Ratio | 14.687 | ▲10.611 | ▲7.827 |
| Solvency Ratio | -4.288 | ▲0.636 | ▼-0.232 |
| Cash Ratio | 14.525 | ▲11.885 | ▲8.621 |
| Price To Earnings Ratio | -8.839 | ▼-6.715 | ▼-4.895 |
| Price To Earnings Growth Ratio | 0.172 | ▼-0.129 | ▲0.132 |
| Forward Price To Earnings Growth Ratio | 0.172 | ▼-0.129 | ▲0.132 |
| Price To Earnings Diluted Ratio | -8.839 | ▼-6.715 | ▼-4.895 |
| Price To Earnings Diluted Growth Ratio | 0.172 | ▼-0.129 | ▲0.132 |
| Price To Book Ratio | 2.958 | ▼-0.480 | ▲0.382 |
| Price To Sales Ratio | 270.321 | ▲201.440 | ▲199.451 |
| Price To Free Cash Flow Ratio | -9.353 | ▼-5.563 | ▲0.151 |
| Price To Operating Cash Flow Ratio | -9.828 | ▼-4.207 | ▲0.701 |
| Debt To Assets Ratio | 0.006 | ▼-0.015 | ▼-0.005 |
| Debt To Equity Ratio | 0.006 | ▼-0.021 | ▼-0.008 |
| Debt To Capital Ratio | 0.006 | ▼-0.020 | ▼-0.008 |
| Long Term Debt To Capital Ratio | 0.006 | ▲0.006 | ▲0.005 |
| Financial Leverage Ratio | 1.077 | ▼-0.249 | ▼-0.181 |
| Working Capital Turnover Ratio | 0.018 | ▼-0.045 | ▼-0.039 |
| Operating Cash Flow Ratio | -4.244 | ▼-2.203 | ▼-1.760 |
| Operating Cash Flow Sales Ratio | -27.506 | ▼-15.251 | ▼-19.446 |
| Free Cash Flow Operating Cash Flow Ratio | 1.051 | ▼-0.432 | ▼-0.081 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | ▲1929.320 |
| Interest Coverage Ratio | 0.000 | 0.000 | ▲1980.120 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -49.525 | ▼-26.596 | ▼-2.900 |
| Capital Expenditure Coverage Ratio | -19.713 | ▼-17.642 | ▲55.744 |
| Dividend Paid And Capex Coverage Ratio | -19.713 | ▼-17.642 | ▲55.744 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -5.857 | ▼-2.658 | ▼-2.344 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.88B | $622.8M | $212.3M | $26.8M | $149.5M | |
| Enterprise value | $1.23B | $484.2M | $115.3M | $6.8M | $100.6M | |
| EV / Sales | 176.73x | 53.56x | 8.22x | 0.00x | 0.00x | |
| EV / Op. cash flow | -6.42x | -4.37x | -15.23x | -0.24x | -5.52x | |
| EV / Free cash flow | -6.12x | -2.95x | -13.73x | -0.23x | -5.50x | |
| EV / EBITDA | -5.86x | -3.20x | -4.12x | -0.19x | -4.20x | |
| Net debt / EBITDA | 3.10x | 0.92x | 3.46x | 0.55x | 2.04x | |
| Current ratio | 14.69x | 4.08x | 6.63x | 3.09x | 5.82x | |
| Income quality | 0.90x | 0.38x | 0.07x | 0.78x | 0.74x | |
| Graham net-net | $7 | $3 | $6 | $1 | $4 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 190.9% | 371.8% | 100.0% | 100.0% | |
| Working capital | $615.8M | $167.0M | $122.9M | $15.3M | $46.9M | |
| Invested capital | $633.4M | $181.4M | $126.5M | $16.3M | $47.8M | |
| Return on assets | -31.1% | -121.9% | -71.9% | -153.4% | -42.7% | |
| Operating ROA | -46.4% | -157.3% | -126.9% | -90.0% | -49.2% | |
| Return on tangible assets | -31.1% | -121.9% | -71.9% | -153.4% | -42.7% | |
| Return on equity | -33.5% | -161.7% | -89.1% | -221.6% | -51.3% | |
| Return on invested capital | -33.5% | -164.4% | -86.2% | -217.8% | -52.0% | |
| Return on capital employed | -33.5% | -164.5% | -86.4% | -220.8% | -52.3% | |
| Earnings yield | -11.3% | -47.0% | -50.3% | -137.7% | -16.5% | |
| Free cash flow yield | -10.7% | -26.4% | -4.0% | -108.0% | -12.2% | |
| Capex / Op. cash flow | -5.1% | -48.3% | -11.0% | -0.9% | -0.4% | |
| Capex / Depreciation | 327.7% | 2545.6% | 114.1% | 39.3% | 10.5% | |
| Capex / Sales | 139.5% | 591.8% | 5.9% | 0.0% | 0.0% | |
| SG&A / Sales | 630.6% | 364.5% | 140.2% | 0.0% | 0.0% | |
| R&D / Sales | 2511.6% | 1432.8% | 164.7% | 0.0% | 0.0% | |
| Stock comp / Sales | 370.1% | 174.2% | 44.4% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 8d | 0d | 0d | |
| Days payables outstanding | 412d | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 8d | 0d | 0d | |
| Cash conversion cycle | -412d | 0d | 8d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+201.3%EV / Sales ▲+230.0%EV / EBITDA ▼-83.1%EV / Op. cash flow ▼-2.055Earnings yield ▲+0.357
Profitability
Return on equity ▲+1.282Return on assets ▲+0.909Return on invested capital ▲+1.309Return on capital employed ▲+1.309Operating ROA ▲+1.109Income quality ▲+0.521Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales ▼-4.523R&D / Sales ▲+10.788
Balance-sheet strength
Current ratio ▲+10.611Net debt / EBITDA ▲+2.187Working capital ▲+448755000.000Invested capital ▲+451978000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+1154.7%EV / Sales n/aEV / EBITDA ▼-39.4%EV / Op. cash flow ▼-0.904Earnings yield ▲+0.052
Profitability
Return on equity ▲+0.178Return on assets ▲+0.116Return on invested capital ▲+0.184Return on capital employed ▲+0.187Operating ROA ▲+0.028Income quality ▲+0.161Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+8.865Net debt / EBITDA ▲+1.059Working capital ▲+568877000.000Invested capital ▲+585636000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-17 argenx VYVGART Hits Phase III Goal in Autoimmune Myositis, Eyes IMNM Filing argenx NASDAQ: ARGX reported positive top-line results from its Phase III ALKIVIA trial of VYVGART Hytrulo in autoimmune myositis, meeting its primary endpoint in a combined population of patients with immune-mediated necrotizing myopathy, or IMNM, and dermatomyositis, or DM.
- 2026-08-17 argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis Study met primary endpoint of mean Total Improvement Score (TIS) at Week 52 in the combined study population of IMNM and DM patients (p=0.0011) Patient improvements observed early and sustained throughout study; consistent treatment effect across IMNM and DM First Phase 3 study to show statistically significant and clinically meaningful improvements in disease activity in IMNM, a subtype with no approved therapy argenx to host a conference call on August 17 th at 2:30 PM CET/ 8:30 AM ET August 17, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced positive topline results from the ALKIVIA Phase 3 study evaluating VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with autoimmune myositis. Study met its primary endpoint (p=0.0011) In the combined immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) population, patients treated with efgartigimod demonstrated statistically significant and clinically meaningful 15.4-point greater improvement in mean Total Improvement Score (TIS) at Week 52 versus placebo (47.95 vs 32.56).
- 2026-08-13 Immunome: Maintaining My ''Strong Buy'' Rating With 2 Catalysts On The Horizon I am maintaining my "Strong Buy" rating on Immunome (IMNM). This decision is driven by FDA acceptance of varegacestat''s NDA and a PDUFA date set for April 2027. The company''s pipeline is diversified, with IM-1021 [ROR1 ADC] in phase 1 for B-cell lymphoma/solid tumors and initial data expected in 2026. The proprietary HC74 TOP1i payload in IM-1021 aims for best-in-class efficacy, targeting resistance and bystander effects beyond Merck''s ROR1 ADC.
- 2026-08-11 Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended June 30, 2026, and provided a business update. “We continue to execute against our strategy of building a diversified targeted oncology company with multiple opportunities to bring needed therapies to patients,” said Clay B. Siegall, Ph.D., President and Chief Executive Of.
- 2026-08-06 Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on August 3, 2026, the Compensation Committee of the Company''s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 176,500 shares of common stock to nine new employees under the Company''s 2024 Induc.
- 2026-07-24 Atika Capital Management LLC Sells 71,441 Shares of Immunome, Inc. $IMNM Atika Capital Management LLC lessened its holdings in Immunome, Inc. (NASDAQ: IMNM) by 21.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 262,900 shares of the company''s stock after selling 71,441 shares during the quarter. Atika Capital
- 2026-07-20 Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the first patient has been dosed in the Phase 1, first-in-human trial of IM-3050, an investigational FAP-targeted radioligand therapy being evaluated in patients with FAP-expressing advanced solid tumors.“FAP is a high-potential target with expression in 75% of solid tumors,” said Bob Lechleider, M.D., Chi.
- 2026-07-12 What This Immunome Sale Means a Day Before a Big FDA Milestone An Immunome insider sold 100,000 shares for $2.4 million based on weighted average prices on July 6, 2026 and July 7, 2026. The transaction represents 32% of the insider''s total equity holdings in the company.
- 2026-07-10 Immunome Stock Up 32% in a Month: Here''s What You Should Know IMNM jumps 32% in a month. This comes as the FDA accepts varegacestat''s NDA for desmoid tumors, with an approval decision expected by April 2027.
- 2026-07-08 Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted its New Drug Application (NDA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action.